By: DelCharco M.D. OB/GYN
Hormone replacement therapy, or HRT, has become increasingly available through a variety of channels: online platforms, wellness clinics, compounding pharmacies, and direct-to-consumer programs that offer hormone prescriptions with minimal clinical evaluation. For women navigating the significant hormonal changes of perimenopause and menopause, the accessibility of these options can feel appealing, particularly when symptoms are disruptive and the path to care seems complicated. But accessibility is not the same as safety, and convenience is not the same as appropriate care. At DelCharco M.D. OB/GYN in Ocala, Florida, physician-supervised hormone replacement therapy is a core part of what we offer, and the distinction between supervised and unsupervised hormone therapy is not a small one.
“Thorough discussion and understanding of treatment options. Dr. Hopper is committed, caring, and knowledgeable. An outstanding physician in every way.”
—DelCharco M.D. OB/GYN Patient Testimonial
What Physician Supervision Actually Involves
Physician-supervised hormone replacement therapy is not simply a matter of having a provider sign off on a prescription. It involves a comprehensive clinical evaluation before any therapy begins, ongoing monitoring throughout treatment, and the clinical judgment to adjust or discontinue therapy as a patient’s health picture evolves.
A thorough initial evaluation includes a complete review of medical and surgical history, a family history assessment (particularly for breast cancer, blood clots, stroke, and cardiovascular disease), a physical exam, and baseline laboratory work. This information determines whether HRT is appropriate for a given patient, which type of hormone is most suitable, what delivery method is safest and most effective, and what dose achieves symptom control at the lowest necessary exposure.
These are not bureaucratic steps. They are the clinical foundation that makes hormone therapy both effective and safe for each individual woman. Skipping them is not streamlining care; it is removing the layer of oversight that protects against harm.
Why Type and Delivery Method Matter
HRT is not a single therapy. It encompasses a range of estrogen formulations, progestogen options, and delivery methods including oral pills, transdermal patches and gels, vaginal rings and inserts, and subcutaneous pellets. Each option has a distinct absorption profile, risk profile, and suitability for different patients.
Transdermal estrogen, for example, does not carry the same elevated blood clot risk as oral estrogen because it bypasses first-pass liver metabolism. This distinction is clinically meaningful for women with certain cardiovascular risk factors. Micronized progesterone, the form most chemically similar to the progesterone the body naturally produces, appears to carry a lower risk profile than synthetic progestins in the available evidence. The choice between estrogen-only and combined therapy depends on whether a woman has a uterus, among other factors.
A provider managing HRT based on a thorough clinical evaluation will match each patient to the formulation and delivery method that provides the best benefit-risk ratio for her individually. A platform operating with minimal clinical contact cannot make that match appropriately.
The Risk Profile Requires Individualized Assessment
HRT is not appropriate for every woman. Contraindications include a personal history of certain hormone-sensitive cancers, a history of blood clots or stroke, active cardiovascular disease, uncontrolled high blood pressure, and active liver disease. These are not absolute rules that apply identically to every woman in every circumstance, but they require careful clinical judgment, not a checklist.
The risks of HRT also depend on factors including the type of hormone, the delivery method, the dose, the timing of initiation relative to menopause, and the duration of use. The “timing hypothesis,” supported by consistent research, shows that initiating hormone therapy in women who are under 60 or within ten years of their last menstrual period produces a substantially different risk profile than initiating it in older women who are more than a decade past menopause. Applying population-level guidelines to an individual patient requires a provider who knows that patient.
Monitoring Is Not Optional
Even for women who are excellent candidates for HRT and who are well-matched to a particular regimen, ongoing monitoring is essential. Annual visits allow the provider to assess whether the current regimen continues to provide benefit, whether symptoms have changed, whether new risk factors have emerged, and whether the dose can be adjusted. Lab work and physical examination inform decisions about continuing, modifying, or discontinuing therapy.
Monitoring is also where potential complications are identified early. Blood pressure trends, lipid changes, and symptom patterns that might signal a need for adjustment are only visible to a provider who is seeing the patient consistently and who has the clinical context to interpret what they find.
“Paula explains the HRT process and my blood work, my entire healthcare process regarding HRT. She answers all of my questions and truly cares and takes her time with me.”
—DelCharco M.D. OB/GYN Patient Testimonial
What Unsupervised or Minimally Supervised HRT Can Miss
When hormone therapy is initiated with minimal clinical evaluation, several important considerations can go unaddressed. Undetected cardiovascular risk factors, such as elevated blood pressure or undiagnosed blood clotting disorders, can be worsened by certain hormone formulations. A history of certain hormone-sensitive conditions, including specific types of breast lesions or endometrial abnormalities, may not be captured in a brief intake form. The interaction between hormone therapy and other medications a woman is taking may not be reviewed. And the dose selected may be based on a standard protocol rather than on what is actually appropriate for that individual’s weight, health history, and symptom severity.
None of these gaps are theoretical. They represent real clinical situations where women were harmed by hormone therapy that was not appropriately matched to their health profile. Physician supervision exists precisely to identify and avoid these situations.
DelCharco M.D. OB/GYN is distinguished in the Ocala area as a practice that specializes in physician-supervised hormone replacement therapy. Our providers bring deep clinical experience to the evaluation, initiation, and ongoing management of HRT. We take the time to understand each patient’s full health picture before making any recommendation, and we remain involved in monitoring and adjusting care over time. Hormone therapy managed this way is a different experience from a subscription box or a wellness app. It is care. Schedule an appointment with our team or call us at (352) 690-6300 to discuss whether HRT is right for you. You can also explore our full range of services to learn more about what we offer.